AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-11. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The lungs have a dual blood supply provided by a bronchial and a pulmonary circulation. The bronchial circulation supplies oxygenated blood to the airways of the lungs, through the bronchial arteries that leave the aorta. There are usually three arteries, two to the left lung and one to the right, and they branch alongside the bronchi and bronchioles. The pulmonary circulation carries deoxygenated blood from the heart to the lungs and returns the oxygenated blood to the heart to supply the rest of the body. The blood volume of the lungs is about 450 millilitres on average, about 9% of the total blood volume of the entire circulatory system. This quantity can easily fluctuate from between one-half and twice the normal volume. Also, in the event of blood loss through hemorrhage, blood from the lungs can partially compensate by automatically transferring to the systemic circulation.
=== Toxicity === At present, the information needed to determine if HMX causes cancer is insufficient. Due to the lack of information, EPA has determined that HMX is not classifiable as to its human carcinogenicity. The available data on the effects on human health of exposure to HMX are limited. HMX causes CNS effects similar to those of RDX, but at considerably higher doses. In one study, volunteers submitted to patch testing, which produced skin irritation. Another study of a cohort of 93 workers at an ammunition plant found no hematological, hepatic, autoimmune, or renal diseases. However, the study did not quantify the levels of exposure to HMX. HMX exposure has been investigated in several studies on animals. Overall, the toxicity appears to be quite low. HMX is poorly absorbed by ingestion. When applied to the dermis, it induces mild skin irritation but not delayed contact sensitization. Various acute and subchronic neurobehavioral effects have been reported in rabbits and rodents, including ataxia, sedation, hyperkinesia, and convulsions. The chronic effects of HMX that have been documented through animal studies include decreased hemoglobin, increased serum alkaline phosphatase, and decreased albumin. Pathological changes were also observed in the animals' livers and kidneys. Gas exchange rate was used as an indicator of chemical stress in Northern bobwhite quail (Colinus virginianus) eggs, and no evidence of alterations in metabolic rates associated with HMX exposure was observed.
However, urea-formaldehyde resin itself has been suggested as appropriate for use in feed for some non-ruminants in at least one UN FAO report, suggesting its use as a binder in feed pellets in aquaculture. There is at least one report of inexpensively priced rice protein concentrate (feed grade) containing non-protein nitrogen being marketed for use in non-ruminants dating back to 2005. In a news item on its website, Jiangyin Hetai Industrial Co., Ltd. warned its customers of low-priced "PSEUDO rice protein" for sale in the market by another unnamed supplier, noting that the contaminant could be detected by analyzing the isoelectric point. It is not clear from that report whether the contaminant in that case was melamine or some other non-protein nitrogen source or whether any contaminated rice protein concentrate made it into the food supply at that time. On 18 April 2007, an ad was posted on the trading website Alibaba.com selling "Esb protein powder" in Xuzhou Anying's name. The product is said to be protein in nature and suitable for livestock and poultry feed, yet claims a crude protein content of 160–300%. It also mentions in passing the product makes use of "NPN" which is an acronym for non-protein nitrogen. Similar ads were placed on other websites, some dated as early as 31 October 2005. Products with similar descriptions were also sold as "EM bacterium active protein forage" by Shandong Binzhou Xinpeng Biosciences Company and "HP protein powder" by Shandong Jinan Together Biologic Technology Development Company.
== Work == From 1946 through 1956 Ettre worked at pharmaceutical and chemical engineering firms in Hungary. In 1956 he was appointed to the position of head of the Industrial Department of the Hungarian Research Institute on Plastics in Budapest. He held the position of chemical engineer at Lurgi AG in Frankfurt am Main, West Germany, where he began to work with gas chromatography. In the United States, Ettre worked at the PerkinElmer Corporation from 1958 until his retirement in 1990; he held the positions of Application Engineer, Product Specialist, Chief Applications Chemist, and Senior Staff Scientist, and finally Senior Scientist. Ettre's major research area was chromatography. His activities covered a variety of fields including surface area studies, trace analysis, detector response, reaction gas chromatography, the retention index system, headspace gas chromatography, and in particular the theory and practice of open-tubular (capillary) column gas chromatography. After his retirement, he focused on the history and evolution of chromatography and its relationship to other scientific disciplines. The history and variations of Hungarian philately in the period 1900–1944 was one of his lesser-known activities, in which he authored several monographs published by the Society for Hungarian Philately.
Several naturally-preserved, unintentional mummies dating from the Incan period (1438–1532 AD) have been found in the colder regions of Argentina, Chile, and Peru. These are collectively known as "ice mummies". The first Incan ice mummy was discovered in 1954 atop El Plomo Peak in Chile, after an eruption of the nearby volcano Sabancaya melted away ice that covered the body. The Mummy of El Plomo was a male child who was presumed to be wealthy due to his well-fed bodily characteristics. He was considered to be the most well-preserved ice mummy in the world until the discovery of Mummy Juanita in 1995. Mummy Juanita was discovered near the summit of Ampato in the Peruvian section of the Andes mountains by archaeologist Johan Reinhard. Her body had been so thoroughly frozen that it had not been desiccated; much of her skin, muscle tissue, and internal organs retained their original structure. She is believed to be a ritual sacrifice, due to the close proximity of her body to the Incan capital of Cusco, as well as the fact she was wearing highly intricate clothing to indicate her special social status. Several Incan ceremonial artifacts and temporary shelters uncovered in the surrounding area seem to support this theory. More evidence that the Inca left sacrificial victims to die in the elements, and later be unintentionally preserved, came in 1999 with the discovery of the Llullaillaco mummies on the border of Argentina and Chile. The three mummies are children, two girls and one boy, who are thought to be sacrifices associated with the ancient ritual of qhapaq hucha.
Sources: en.wikipedia.org
=== Stress === Prolonged chronic stress may contribute to metabolic syndrome via dysregulation of the hypothalamic–pituitary–adrenal axis. Elevated cortisol can raise glucose and insulin levels, promoting visceral adiposity, insulin resistance, dyslipidaemia, and hypertension, and has effects on bone turnover.
== Other sources == Legwold, Gary (1991). The Last Word on Lefse. Adventure Publication. ISBN 978-0-934860-78-9. Ojakangas, Beatrice (1999). The Great Scandinavian Baking Book. University of Minnesota Press. ISBN 978-0-8166-3496-5.
At the highest trophic level is typically an apex predator, a consumer with no natural predators in the food chain model. When any trophic level dies, detritivores and decomposers consume their organic material for energy and expel nutrients into the environment in their waste. Decomposers and detritivores break down the organic compounds into simple nutrients that are returned to the soil. These are the simple nutrients that plants require to create organic compounds. It is estimated that there are more than 100,000 different decomposers in existence. Models of trophic levels also often model energy transfer between trophic levels. Primary consumers get energy from the producer and pass it to the secondary and tertiary consumers.
Overview of all the structural information available in the PDB for UniProt: Q9UBU3 (Human Appetite-regulating hormone) at the PDBe-KB. Overview of all the structural information available in the PDB for UniProt: Q9EQX0 (Mouse Appetite-regulating hormone) at the PDBe-KB.
=== Alprostadil === Alprostadil is used for two main purposes: the treatment of newborns with congenital heart defects and in treatment of erectile dysfunction. Some babies are born with heart defects which compromise blood flow to the body. In some defects, including tetralogy of Fallot, aortic valvular atresia, and Eisenmenger pulmonary hypertension, alprostadil is given intravenously by a nurse until surgery can be performed to repair the defect. The medication maintains a patent ductus arteriosus. The ductus arteriosus is a shortcut between the aorta and pulmonary artery, two large vessels branching off the heart. This shortcut allows the fetus to maintain blood flow before birth. However, it closes shortly after birth when the newborn can breathe oxygen. In babies with certain congenital defects, however, it's essential to keep the ductus arteriosus open to ensure at least some blood flow throughout the body. Side effects include decreased breathing or a lack of breathing at high doses. The medication can also cause hypotension, or low blood pressure. Alprostadil is also used for adults with erectile dysfunction. It is typically given when other medications are ineffective. The medication relaxes smooth muscle and allows the arteries in the corpus cavernosum of the penis to dilate. Blood then flows to the penis. This blood flow compresses the veins which drain blood from the penis, trapping the blood in the corpus cavernosum. This process leads to erection.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.